Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR

Eventide Asset Management LLC grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 562,990 shares of the company’s stock after purchasing an additional 37,852 shares during the quarter. Eventide Asset Management LLC owned about 0.79% of Kymera Therapeutics worth $24,569,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in KYMR. Farther Finance Advisors LLC increased its holdings in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after purchasing an additional 540 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after acquiring an additional 770 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics in the 1st quarter worth $68,000. Raymond James Financial Inc. purchased a new position in shares of Kymera Therapeutics during the 2nd quarter worth $73,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kymera Therapeutics by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock valued at $110,000 after acquiring an additional 343 shares during the last quarter.

Kymera Therapeutics Stock Up 2.1%

Shares of NASDAQ KYMR opened at $89.68 on Friday. The business’s 50 day moving average is $64.77 and its two-hundred day moving average is $51.85. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The firm has a market cap of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. Analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce Booth sold 229,809 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57. Following the completion of the transaction, the director owned 686,477 shares in the company, valued at approximately $62,970,535.21. The trade was a 25.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jared Gollob sold 59,576 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the sale, the insider directly owned 109,992 shares in the company, valued at approximately $6,755,708.64. The trade was a 35.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 597,805 shares of company stock worth $46,839,199 over the last 90 days. 16.01% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada began coverage on shares of Kymera Therapeutics in a research report on Tuesday, September 16th. They set an “outperform” rating and a $70.00 price objective for the company. Wells Fargo & Company raised their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, Oppenheimer lifted their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $112.80.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.